FDA questions Remoxy approval; NZ orders Astra to aid inquiry;

> An FDA memo Monday questioned whether Remoxy, a proposed controlled-release oxycodone pill by Pain Therapeutics and King Pharmaceuticals, is truly tamper-resistant. Report

> New Zealand's Court of Appeal dismissed an appeal by AstraZeneca that it did not have to provide information to a Commerce Commission inquiry into the supply of a life-saving cardiovascular drug. Report

> Israel's Syneron reported a drop in net income to $2.2 million on revenues of $28.5 million for the third quarter. Release

> An Indiana woman has filed a lawsuit seeking damages from Pfizer after June floodwaters breached a containment pond on the company's property, sending polychlorinated biphenyls, or PCBs, onto her property. Report

> Hungarian drugmaker Richter Gedeon cut its expected growth in the Russian market to zero from the 10 percent expected in August, but predicted 5 percent 2008 sales growth for the overall company. Report

> Hungary's Egis Pharmaceuticals says that it's expecting the pace of price cuts in its home market to continue to decrease and that it's looking for acquisitions in the region. Report

> Dutch biotechnology company Crucell reported its first quarterly profit, $15.86 million, compared with a $5 million-plus loss in the same quarter last year. Report

> Intervet/Schering-Plough Animal Health launched Nuflor Minidose, a new antibiotic formulation for the treatment and prevention of bacterial pneumonia. Report

> Pharmaceutical packaging company Compass Pharma Services announced it has redesigned its customer service organization and processes. Release

> Zydus Cadila said that the company acquired Etna Biotech, the wholly owned subsidiary of the Dutch biopharma company Crucell. Report

> Looking to cut costs and focus on fewer development programs, Exelixis announced that it is laying off 78 people--10 percent of its workforce. Report

> ArQule and Daiichi Sankyo have formed an R&D partnership with two separate agreements. Report

> GlaxoSmithKline and XenoPort have withdrawn their NDA for Solzira, a treatment for moderate-to-severe primary Restless Legs Syndrome. Report

> Amgen's top management touted the company's strategy and pipeline at a meeting of Amgen securities analysts and investors in New York City. Report

> California-based Xoma is restructuring its collaboration pact with Novartis Vaccines and Diagnostics. Report

> The University of Liverpool and IOTA NanoSolutions have developed man-made nanoparticles that could increase the effectiveness of antibacterial treatments. Report

> Although the economy is clearly the priority for the new President-elect, Barack Obama's still growing team has indicated stem cell research is among the top issues Obama is likely to tackle once in office. Report

Emerging Drug Developer: OncoMed

And Finally... Not a single European country is adequately prepared for the threat of an influenza pandemic, a senior EU disease control official warned on Monday. Report

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.